BR0101527A - Ligandos de receptores de tiróide - Google Patents

Ligandos de receptores de tiróide

Info

Publication number
BR0101527A
BR0101527A BR0101527-3A BR0101527A BR0101527A BR 0101527 A BR0101527 A BR 0101527A BR 0101527 A BR0101527 A BR 0101527A BR 0101527 A BR0101527 A BR 0101527A
Authority
BR
Brazil
Prior art keywords
compounds
thyroid
receptor ligands
thyroid receptor
disease
Prior art date
Application number
BR0101527-3A
Other languages
English (en)
Inventor
Yuan-Ching Phoebe Chiang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0101527A publication Critical patent/BR0101527A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Patente de Invenção: "LIGANDOS DE RECEPTORES DETIRóIDE". A invenção refere-se a compostos de fórmula (I)tiazolidinodiona, oxadiazolidinodiona, e triazolona que sãocompostos receptores de ligandos de tiróide. A invenção refere-setambém a composições farmacêuticas e kits compreendendo taiscompostos e métodos de tratar obesidade, excesso de peso,hiperlipidemia, glaucoma, arritmias cardíacas, distúrbios de pele,doença de tiróide, hipotiroidismo, câncer da tiróide, diabetes,aterosclerose, hipertensão, doença cardíaca coronária,insuficiência cardíaca congestiva, hipercolesterolemia, depressão,e osteoporose utilizando tais compostos.
BR0101527-3A 2000-04-21 2001-04-19 Ligandos de receptores de tiróide BR0101527A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19904400P 2000-04-21 2000-04-21

Publications (1)

Publication Number Publication Date
BR0101527A true BR0101527A (pt) 2001-11-20

Family

ID=22735966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0101527-3A BR0101527A (pt) 2000-04-21 2001-04-19 Ligandos de receptores de tiróide

Country Status (7)

Country Link
EP (1) EP1148054B1 (pt)
JP (1) JP2002053564A (pt)
AT (1) ATE310733T1 (pt)
BR (1) BR0101527A (pt)
CA (1) CA2344574C (pt)
DE (1) DE60115132T2 (pt)
ES (1) ES2248242T3 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
ES2253495T3 (es) * 2001-09-26 2006-06-01 Pfizer Products Inc. Acidos indol carboxilicos como ligandos de receptores tiroideos.
WO2003045363A2 (en) * 2001-11-30 2003-06-05 Solvay Pharmaceuticals Gmbh Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
US7696193B2 (en) 2002-12-20 2010-04-13 Glaxo Group Limited Benzazepine derivatives for the treatment of neurological disorders
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
BRPI0508220A (pt) 2004-02-27 2007-07-17 Hoffmann La Roche derivados de pirazol heteroarila fundidos
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
EP1747202A1 (en) 2004-02-27 2007-01-31 F.Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
JP2008528628A (ja) 2005-01-31 2008-07-31 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性二環式化合物
FR2887442A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
US20090131420A1 (en) * 2005-10-07 2009-05-21 Pandey Surendrakumar S Novel Heterocyclic Analogs of Biphenyl Ethers
WO2007132475A1 (en) * 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
WO2008062469A2 (en) 2006-10-31 2008-05-29 Cadila Healthcare Limited Selective tr-beta 1 agonist
RU2527948C2 (ru) 2009-04-20 2014-09-10 Мицубиси Танабе Фарма Корпорейшн Новый агонист бета рецептора тиреоидного гормона
CN104430309A (zh) * 2014-11-17 2015-03-25 宁夏中远天宇科技有限公司 一种新型的20%浓度的三唑酮乳油的物理生产工艺的投料配比
WO2019054514A1 (ja) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 網膜組織の製造方法
CA3132804A1 (en) 2019-03-13 2020-09-17 Sumitomo Dainippon Pharma Co., Ltd. Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
CA3194226A1 (en) 2020-09-11 2022-03-17 Riken Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same
JPWO2022054924A1 (pt) 2020-09-11 2022-03-17
JPWO2023090427A1 (pt) 2021-11-19 2023-05-25

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
WO1993003021A1 (en) * 1991-07-30 1993-02-18 Yamanouchi Pharmaceutical Co., Ltd. Novel bisheterocyclic derivative or salt thereof
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
WO1999024415A1 (fr) * 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Agonistes du recepteur du retinoide
EP1109796A1 (en) * 1999-07-01 2001-06-27 Geron Corporation Telomerase inhibitors and methods of their use
JP2001031660A (ja) * 1999-07-14 2001-02-06 Iyaku Bunshi Sekkei Kenkyusho:Kk 甲状腺ホルモン様作用物質
EA200200311A1 (ru) * 1999-08-31 2002-08-29 Максиа Фармасьютикалз, Инк. Бензилиден-тиазолидиндионы и аналоги и их применение для лечения диабета

Also Published As

Publication number Publication date
ES2248242T3 (es) 2006-03-16
DE60115132D1 (de) 2005-12-29
JP2002053564A (ja) 2002-02-19
EP1148054A1 (en) 2001-10-24
CA2344574A1 (en) 2001-10-21
EP1148054B1 (en) 2005-11-23
CA2344574C (en) 2007-02-20
ATE310733T1 (de) 2005-12-15
DE60115132T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
BR0101527A (pt) Ligandos de receptores de tiróide
YU74102A (sh) Malonaminske kiseline i njihovi derivati kao ligandi tireoidnog receptora
EP1088819A3 (en) 6-azauracil derivatives as thyroid receptor ligands
PT1033364E (pt) Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
BR0203877A (pt) ácidos indol carboxìlicos como ligandos do receptor da tireóide, bem como composições e aplicações farmacêuticas compreendendo os mesmos
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
WO1998047505A9 (fr) Antagoniste de recepteur de neuropeptide y
ATE356119T1 (de) Pyrimidinone als melanin concentrating hormone receptor 1
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
DE60022366D1 (de) Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
WO2004099150A3 (en) 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
EP1423370A4 (en) COMPOUNDS BINDING TO THE NUCLEAR FXR-NR1H4 RECEPTOR
BR0100156A (pt) Compostos tetrazol como ligandos de receptor de tiróide
EP1818325A3 (en) 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
DK1054887T3 (da) Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister
NO983002L (no) Vitronectin-reseptor-antagonister
PT1349843E (pt) Derivados de tiazolo e de oxazolo como activadores dos receptores activados por proliferadores de peroxissomas humanos
EP0893498A3 (en) cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
NO996577D0 (no) Fremgangsmåte ved fremstilling av perhydroisoindol
EP1253139A3 (en) Multioligoanilinated fullerenes
PT1334094E (pt) Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol
EP0884387A3 (en) Human 7-transmembrane receptor HLWAR77
WO2005049589A3 (en) Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
NO20033401L (no) Kjemiske forbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.